Aurealis Therapeutics Raises $10 Million in an Oversubscribed Series A Financing to Accelerate Phase 2 Clinical Studies in Chronic Wounds and Preclinical Development in Oncology with Its First-in-Class Technology Platform
Aurealis Therapeutics, a synthetic biology company developing ground-breaking cell and gene therapies for high unmet medical needs, has raised over $10 million through a Series A financing round co-led by Lynx Financial and TESI (Finnish Industry Investment Ltd) with participation of Huahai Pharmaceuticals, family offices and biotech HNWIs. The funds will be primarily used to […]
